Patient demographics and characteristics
| . | IM cohort . | Historical cohort . |
|---|---|---|
| Sex, no. (%) | ||
| Male | 94 (64) | 141 (61) |
| Female | 51 (36) | 90 (39) |
| Age, y, median (mean) | 40.1 (40.6) | 40.6 (39.0) |
| Disease phase at diagnosis, no. (%) | ||
| Chronic phase | 117 (81) | — |
| Accelerated phase and higher CP | 22 (15) | — |
| Blast crisis | 6 (4) | — |
| Disease phase at transplantation, no. (%) | ||
| Chronic phase or better* | 72 (50) | 183 (79) |
| Accelerated phase and higher CP | 60 (41) | 38 (17) |
| Blast crisis | 13 (9) | 10 (4) |
| Interval from diagnosis to transplantation, y | 1.70 | 0.94 |
| IM therapy duration, y, median (range) | 0.83 (0.25-3.92) | — |
| Interval from IM cessation to transplantation, wk EBMT score, no. (%) | 2-4 | — |
| 0 and 1 | 10 (7) | 29 (13) |
| 2 | 28 (19) | 65 (28) |
| 3 and 4 | 73 (50) | 111 (48) |
| 5+ | 34 (24) | 17 (7) |
| Unknown | — | 9 (4) |
| . | IM cohort . | Historical cohort . |
|---|---|---|
| Sex, no. (%) | ||
| Male | 94 (64) | 141 (61) |
| Female | 51 (36) | 90 (39) |
| Age, y, median (mean) | 40.1 (40.6) | 40.6 (39.0) |
| Disease phase at diagnosis, no. (%) | ||
| Chronic phase | 117 (81) | — |
| Accelerated phase and higher CP | 22 (15) | — |
| Blast crisis | 6 (4) | — |
| Disease phase at transplantation, no. (%) | ||
| Chronic phase or better* | 72 (50) | 183 (79) |
| Accelerated phase and higher CP | 60 (41) | 38 (17) |
| Blast crisis | 13 (9) | 10 (4) |
| Interval from diagnosis to transplantation, y | 1.70 | 0.94 |
| IM therapy duration, y, median (range) | 0.83 (0.25-3.92) | — |
| Interval from IM cessation to transplantation, wk EBMT score, no. (%) | 2-4 | — |
| 0 and 1 | 10 (7) | 29 (13) |
| 2 | 28 (19) | 65 (28) |
| 3 and 4 | 73 (50) | 111 (48) |
| 5+ | 34 (24) | 17 (7) |
| Unknown | — | 9 (4) |
IM indicates imatinib mesylate; —, data not available or not applicable.
“Better” indicates patients in chronic phase with a major or complete cytogenetic response on IM at the time of transplantation.